Connect Biopharma Holdings Limited CNTB
Set alert
At close · Oct 30
After hours · Oct 30, 6:56 PM ET
- YTD
- -71.55%
- 1 year
- -48.25%
- Open
- 0.827
- Prev close
- 0.8354
- Mkt cap
- 50.52M
- Vol
- 2.50M
- Avg vol
- 3.96M
- EPS
- -1.19
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7805
- High
- 0.8749
- Forward P/E
- -5.04
- Beta
- -0.31
- Short ratio
- 1.93
- Inst. own
- 44.43%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 30, 2023
- 50-d avg
- 1.12
- 200-d avg
- 1.34
- 1y target
- 7.00
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 5, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 29, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 3, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 2, 2026 | 2 months ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
Key statistics
- Market cap
- 55.66M
- Enterprise value
- -57.37M
- Trailing P/E
- 0.00
- Forward P/E
- -5.04
- PEG ratio
- 0.00
- Price / sales
- 2.31
- Price / book
- 0.50
- EPS (TTM)
- -0.39
- Beta
- -0.31
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -88.66%
- Revenue (TTM)
- 24.12M
- Revenue growth
- 0.00%
- Free cash flow
- -17.08M
- Total cash
- 110.24M
- Total debt
- 325.00K
- Return on equity
- -17.92%
- Shares outstanding
- 55.25M
- Short % of float
- 0.18%
- 50-day average
- 1.12
- 200-day average
- 1.34
Analyst view
Consensus: none
- Target (low)
- 6.00
- Target (mean)
- 7.00
- Target (high)
- 8.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 30, 2023
Expected Mar 30, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 30, 2023 | Dec 1, 2022 | -0.48 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 17, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 4, 2024 | HC Wainwright & Co. | init | — | Buy |
| Sep 13, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Feb 8, 2023 | SVB Leerink | main | — | Outperform |
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- connectbiopharm.com
News
- HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
- Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
- Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
- Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
- Leerink Partners Assumes Connect Biopharma Hldgs at Outperform, Announces Price Target of $4
- HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
- Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast
- Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
- HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
Your note
Sign in to keep a note on CNTB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BML Capital Management, LLC | 3.79% | 2,093,232 | 2.11M | Sep 29, 2024 |
| O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC) | 0.92% | 510,701 | 514.48K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.32% | 175,500 | 176.80K | Sep 29, 2024 |
| Callan Capital LLC | 0.08% | 41,823 | 42.13K | Sep 29, 2024 |
| Keudell/Morrison Wealth Management | 0.06% | 33,450 | 33.70K | Sep 29, 2024 |
| Royal Bank of Canada | 0.06% | 30,600 | 30.83K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 27,961 | 28.17K | Oct 30, 2024 |